Pharma companies could develop multiple small molecule drugs for related indications, rather than focus on a single molecule, to allow for staggered launch dates that would protect some uses from Medicare price negotiation beginning nine years after approval, Eli Lilly and Company CEO David Ricks suggested during a JP Morgan webinar on the impact of the Inflation Reduction Act 14 June.
Medicare Negotiation Workarounds: Lilly’s Ricks On Big Pharma Strategies For Small Molecule Drugs
A vocal critic of the way Medicare price negotiation program treats small molecule drugs, the Lilly CEO and offers possible scenarios of how developers may react.
